27.03.2012 - The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which takes off with ten proprietary ADC oncology programmes in the pipeline.
Among them are ADCs against prostate, lung, renal, breast and blood cancers. Bringing the cytotoxic therapeutics to the desired cancer cells with the help of antibodies has some advantages: ADCs are thought to be target-selective and highly potent. They have fewer side effects and could minimize drug resistance. "We believe that ADCs will represent a significant medical breakthrough in cancer therapy over the coming decade", says Celtic co-founder Stephen Evans-Freke. ADC Therapeutics can rely on the know-how of London's very own Spirogen, an ADC company controlled by Celtic. Spirogen's PBD (proprietary pyrrolobenzodiazepines) 'payload' technology constitutes, if anything, the 'best-in-class' ADC cytotoxic weapon ("warhead"). Scientific wisdom is also provided by British Cancer Research Technology Ltd as a shareholder and US-specialists Samuel Broder and Barrie Ward as non-executive directors. Celtic Therapeutics was founded in 2007 by Evans-Freke and Peter B. Corr, who retired from pharmaceutical giant Pfizer in 2006. Evans-Freke outlines the new company's strategy as follows: "The anticipated investment of up to $50 million into ADC Therapeutics will lead to clinical proof of concept in 2-3 lead oncology programmes. We are committed to fully fund ADC Therapeutics and will raise additional capital if warranted." After having resilient Phase II data promising ADCs could be then contracted to pharma giants.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.